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Background: To survey in vitro susceptibilities of
doripenem and other three carbapenems against clinically
important isolates from patients hospitalized in intensive
care units.
Methods: A total of 1311 isolates were studied. MICs were
determined by the agar dilution method (CLSI).
Conclusions: In comparison with other carbapenems,
doripenem exhibited better in vitro activity than imipenem
and similar in vitro activity to meropenem against the Enter-
obacteriaceae. It also showed better in vitro activity than
meropenem and imipenem against Pseudomonas aerugi-
nosa. The activity of doripenem was similar to imipenem
against Acinetobacter baumannii and better than that of
meropenem.
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Objectives: To compare the difference between antimi-
crobial susceptibilities in non-nosocomial and nosocomial
infections in a region with low (Denmark [DK]) versus a
region with high prevalence of resistant bacterial strains
(Israel [IL]).
Methods: The study was based on in-vitro susceptibil-
ities of clinically signiﬁcant bacteremic isolates collected
from adults between 2005—2006 at Copenhagen University
Hospital, Hvidovre (DK) (n = 1308) and between 1988—2004
at Rabin Medical Center (IL) (n = 7589). The isolates
included Escherichia coli, Klebsiella spp., Streptococcus
pneumoniae, Streptococcus viridans, Coagulase-positive
staphylococci, Coagulase-negative staphylococci, Entero-
coccus spp. Bacteremia was deﬁned as nosocomial if it
occurred 48 h or more following hospital admission. For each
pathogen and antibiotic we calculated the Odds Ratios (OR)
for non-nosocomial infection being more susceptible than
nosocomial.
Results: Nosocomial infections were less frequent in DK
than in IL (25% vs. 43% of all infections). The results for E.
coli (the most prevalent pathogen: 43% in DK and 34% in IL)
and Coagulase-negative staphylococci are shown in the table
below. The highest ORs for E. coli in DK (15.3) and IL (3.7)
were observed for Ceftazidim and Ceftriaxone, respectively.
The ORs for E. coli in DK differed statistically from the ORs in
IL for Ceftazidim and Cefuroxime (P < 0.05). For ampicillin
and E. coli the ORs were 1.0 in DK and 1.3 in IL, indicat-
ing that for this drug/pathogen combination both hospitals
reached the same equality in resistance between hospi-
tal and community. The observed ORs for Klebsiella spp.,
S. pneumoniae and Enterococcus spp. for most drugs were
higher in DK. In the case of Coagulase-positive staphylococci
and S. viridans all ORs in DK were statistically non-signiﬁcant
and did not differ signiﬁcantly from the corresponding ORs
in IL.
Conclusion: ORs in the environment with low preva-
lence of resistant pathogens (DK) are generally higher than
in the environment with high resistance (IL). A possible
explanation of the large difference between antimicrobial
susceptibilities in non-nosocomial vs. nosocomial infections
in DK is a low consumption of antibiotics in community in
this country.
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